Phase 2 clinical trial to investigate the safety and how both PF-04937319 and sitigliptin work to control blood sugar, inadequately controlled on metformin, in people who have been diagnosed with Type 2 Diabetes within the past 5 years To evaluate the dose-response of PF-04937319, administered once daily over 12 weeks in adults with T2DM on stable doses of metformin, on glycemic control.

• Country None
• organs None
• Specialty None

A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED ACTIVE COMPARATOR, MULTICENTER STUDY TO COMPARE 5 DOSE REGIMENS OF CP-690,550 AND ADALIMUMAB VERSUS PLACEBO, ADMINISTERED FOR 6 MONTHS IN THE TREATMENT OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS The primary objective is to characterize the dose-response of CP-690-550 over the range of 1-15 mg BID on ACR-20 response criteria at 12 weeks.

• Country None
• organs None
• Specialty None

Pfizer A6181055 : Essai de phase 2 évaluant l’activité et la tolérance d’un traitement par sunitinib, chez des patients ayant un carcinome hépatocellulaire inopérable. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Unresectable Hepatocellular Carcinoma.

• Country France
• organs Primitif du foie
• Specialty Thérapies Ciblées

Phase 3 Study of Inotuzumab Ozogamicin versus Investigator's Choice of Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia To compare the hematological remission, defined as CR (both CR and CRi), as reported by the external independent endpoint adjudication committee, in patients with relapsed/refractory ALL randomized to...

• Country None
• organs None
• Specialty None

A study on the efficacy of the combination of growth hormone (GH) and gonadotropin releasing hormone analogues (GnRHa) on adult height in children with idiopathic short stature Not provided at time of registration

• Country Netherlands
• organs None
• Specialty None

The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure The primary objective of this trial is to evaluate the efficacy and safety of eplerenone plus standard heart failure (HF) therapy versus placebo plus standard HF therapy on the cumulative incidence of...

• Country None
• organs None
• Specialty None

A study to test if PF-06439535 plus Paclitaxel-Carboplatin compared to Bevacizumab plus Paclitaxel-Carboplatin is an effective treatment in patients with advanced non-squamous non-small cell lung cancer The primary objective of this study is to compare the confirmed objective response rate (ORR) by Week 19 following treatment with bevacizumab-Pfizer in combination with paclitaxel and carboplatin to b...

• Country None
• organs None
• Specialty None

Pfizer A4021020 : Essai de phase 1-2 évaluant l’efficacité et la tolérance d’un traitement par CP-751,871 chez des patients ayant une tumeur de la famille des sarcomes d’Ewing. [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité et la tolérance d’un traitement par CP-751,871 chez des patients ayant une tumeur de la famille des sarcomes d’Ewing, et pour lesquels il n'existe pa...

• Country France
• organs Sarcomes
• Specialty Thérapies Ciblées

Pfizer ADVIGO 1016 : Essai de phase 3 randomisé évaluant l’efficacité et la tolérance de l’association de l’anticorps CP-751,871 au paclitaxel et au carboplatine, chez des patients ayant un cancer du poumon non à petites cellules. [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité de l’ajout du CP- 751,871(anticorps anti-IGF-1R) à une chimiothérapie par paclitaxel et carboplatine, chez des patients ayant un cancer du poumon non...

• Country France
• organs Poumon, type non à petites cellules
• Specialty Chimiothérapie, Thérapies Ciblées

PHASE 2, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, 4-WEEK INPATIENT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TWO FIXED DOSES OF PF-02545920 COMPARED TO PLACEBO IN THE TREATMENT OF ACUTE EXACERBATION OF SCHIZOPHRENIA USING RISPERIDONE AS AN ACTIVE CONTROL •To evaluate the efficacy of PF-02545920 in the treatment of acute exacerbation of schizophrenia during a 4-week double-blind treatment period using the Positive and Negative Syndrome Scale (PANSS) to...

• Country None
• organs None
• Specialty None